Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program

Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause support

Nearly 45% of Dario's current book of business is women over age 40 who could potentially benefit from Dario Women™

Dario's expanding multi-condition platform addresses a larger share of clients' membership bases, delivering greater value to payers while increasing the Company's annual recurring revenue base

NEW YORK, Oct. 26, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that a leading regional grocery retailer client has expanded its contract with Dario to add Dario Women™, the Company's recently launched women's health solution supporting women navigating perimenopause and menopause symptoms. The expanded program will be offered to eligible insured employees in January 2027.

The client, a leading regional grocery retailer with over 200 stores and more than 19,000 employees, has used Dario's cardiometabolic solution since the beginning of 2025. Based on employee demand, the client was actively seeking a Women's Health solution in the market and selected Dario's newly-launched program after evaluation in collaboration with their benefit consultant.  In addition to expanding the relationship, this extension allows Dario's multi-condition platform to accelerate favorable cardiometabolic health outcomes and associated downstream cost savings.    

Dario Women launched in August 2026 as an extension of Dario's provider-backed cardiometabolic platform, as women in perimenopause/menopause are among the highest-cost members in any employer population, with 46% higher healthcare spending. The program combines AI-powered engagement, personalized human-led behavioral coaching and access to licensed healthcare providers to support women navigating perimenopause and menopause, including optional clinical evaluation for hormone replacement therapy when medically appropriate. Dario Women supports members navigating midlife transitions, which often manifest in changes or disruptions to weight, sleep, mood or emotion, musculoskeletal, cardiometabolic risk and more.

"This client's decision to expand its program demonstrates two important parts of our growth strategy: our cardiometabolic platform is delivering value that helps us retain and expand with existing clients, and we are successfully adding new solutions that mirror the health requirements of our clients' evolving populations, addressing a larger share of their insured members," said Erez Raphael, Chief Executive Officer of Dario. "Demand from the client's employees for perimenopause support also validates our decision to launch Dario Women. With nearly 45% of our current book of business comprising women over age 40, we see a significant opportunity to expand Dario Women across our existing client base while using DarioIQ's AI-driven personalization to address the interconnected needs of women across weight, sleep, mood and cardiometabolic health."

The expansion provides further evidence of Dario's land-and-expand strategy, in which demonstrated results with existing clients create opportunities to add conditions and increase revenue per customer with little incremental customer acquisition investment.

About DarioHealth Corp.

DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected launch of the program with the client and the timing thereof; the ability of the contract expansion with the client to expand the reach of the Company's Dario Woman program; the ability of the contract extension to accelerate favorable cardiometabolic health outcomes and associated downstream cost savings; and the scalability, growth potential and expected benefits of the Company's "land-and-expand" strategy and capabilities of the Dario Women program. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
[email protected] 
+1-201-785-6310

Rob Halpern
SVP Marketing
[email protected] 

SOURCE DarioHealth Corp.